



THC BIOMED INTL LTD.
P.O. Box 20033 Towne Centre
Kelowna, B.C. V1Y 9H2
www.thcbiomed.com

THC Receives Good Manufacturing Practice (“GMP”) Certification

THC - CSE

THCBF - OTC

TFHC - F

Vancouver, British Columbia – (February 22, 2018) THC BioMed Intl Ltd. (CSE: THC), ("THC" or the "Company") announces that it has received Good Manufacturing Practice (“GMP”) certification for the production of Marijuana Plants and dried Marijuana.

THC has been assessed and meets the requirements of GOOD MANUFACTURING PRACTICE under the Codex Alimentarius Commission, Recommended International Code of Practices, General Principles of Food Hygiene, CAC/RCP 1-1969, Rev. 4 (2003) for the production of Marijuana Plants, dried Marijuana (Propagation, Growing, Harvesting, Drying, Curing and Packaging).

“This certification is significant. It recognizes our high standards and now paves the way for THC BioMed International to export its products into international markets. We are excited to begin the process of exporting our products to Europe and other markets,” said John Miller, President and CEO of THC, “We have begun the process of strengthening our international presence. The international cannabis market displays strong signs of growth and signals indicate a strong demand for high-grade cannabis products internationally.”

“Our expansion in anticipation of the recreational cannabis market is on target and we expect to introduce an additional 10 cannabis production rooms within the next few weeks,” said Mr. Miller.

About THC

THC is an ACMPR Licensed Producer and Canada’s largest supplier of legal Cannabis Genetics. THC is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available.
www.thcbiomed.com

President and CEO:

John Miller
THC Biomed Intl Ltd.
T: 1-844-THCMEDS
E: info@thcbiomed.com

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that: (a) THC will export its products into international markets, (b) THC will export its products to Europe and other markets, (c) there will be a strong demand for high-grade cannabis products internationally, (d) THC will introduce another 10 production rooms within the next few weeks, and, (e) THC will be in the forefront of this rapidly growing industry.

THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.